These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 16009050

  • 1. Differential effects of alternatives to hormone replacement therapy in postmenopausal healthy women.
    Bjarnason NH.
    Dan Med Bull; 2005 May; 52(2):64-81. PubMed ID: 16009050
    [No Abstract] [Full Text] [Related]

  • 2. [Selective estrogen receptor modulators (SERM's) in postmenopausal women].
    Kleiverda G.
    Ned Tijdschr Geneeskd; 1999 Nov 27; 143(48):2446-7. PubMed ID: 10608980
    [No Abstract] [Full Text] [Related]

  • 3. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M.
    Clin Calcium; 2004 Oct 27; 14(10):105-10. PubMed ID: 15577140
    [Abstract] [Full Text] [Related]

  • 4. Effects of estrogens and selective estrogen receptor modulators on indicators of cardiovascular health in postmenopausal women.
    Klein KP, Herrington DM.
    Medscape Womens Health; 2002 Oct 27; 7(5):2. PubMed ID: 12466731
    [No Abstract] [Full Text] [Related]

  • 5. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
    Higuchi T, Mizunuma H.
    Clin Calcium; 2004 Oct 27; 14(10):81-4. PubMed ID: 15577136
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Effects of estrogen and selective estrogen receptor modulators on osteoporosis].
    Urano T.
    Clin Calcium; 2005 Apr 27; 15(4):591-5. PubMed ID: 15802770
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Osteoporosis guidelines.
    Yendt ER.
    CMAJ; 2003 Jun 24; 168(13):1644; author reply 1645-6. PubMed ID: 12821611
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Drugs for prevention and treatment of postmenopausal osteoporosis.
    Treat Guidel Med Lett; 2002 Nov 24; 1(3):13-8. PubMed ID: 15529101
    [No Abstract] [Full Text] [Related]

  • 17. The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.
    Archer DF.
    Menopause; 2011 Jan 24; 18(1):6-7. PubMed ID: 21173718
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Drugs in development for the treatment of osteoporosis:Raloxifene].
    Taga M.
    Nihon Rinsho; 2002 Mar 24; 60 Suppl 3():572-80. PubMed ID: 11979956
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.